Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 13, 2026 07:05 ET | Source: Longeveron

Longeveron Announces Presentation of Clinical Data at the 2026 Alzheimer’s Association International Conference (AAIC) that Indicate Its Cellular Therapy Laromestrocel Reduced Neuroinflammation in Patients with Alzheimer’s Disease

Longeveron reports new data analysis for its stem cell therapy laromestrocel in mild Alzheimer's disease at AAIC 2026.
July 13, 2026 04:50 ET | Source: Vandria SA

New Phase 1 Data Show VNA-318 Mechanism of Action Translates to Humans, Supporting Potential to Address Medical Needs of People with Neurodegenerative Diseases

New Phase 1 data show VNA-318's mechanism of action translates from preclinical models into human biology; clear pharmacodynamic effect on the human brain
June 22, 2026 08:00 ET | Source: Medidata Solutions, Inc.

Medidata Unveils New Academic Board to Bridge the Gap Between Research and Patient Care

NEW YORK, June 22, 2026 (GLOBE NEWSWIRE) -- Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, today introduced its Academic Site...
June 18, 2026 09:20 ET | Source: Longeveron

New Phase 2a Clinical Data Analysis of Stem Cell Therapy Laromestrocel in Mild Alzheimer’s Disease Accepted for Poster Presentation at the 2026 Alzheimer’s Association International Conference (AAIC)

Longeveron stem cell therapy Phase 2a clinical data in Alzheimer's disease selected for poster presentation at 2026 AAIC.
May 28, 2026 08:00 ET | Source: Medidata Solutions, Inc.

Medidata’s Next-Gen AI Imaging Solution Delivers Unprecedented Speed and Precision for Clinical Trials

NEW YORK, May 28, 2026 (GLOBE NEWSWIRE) -- Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions, today unveiled its enhanced, AI-powered imaging solution, within the...
May 28, 2026 04:00 ET | Source: Anaveon

Anaveon Reports Clinical Benefit of ANV600 in the EXPAND-1 Phase 1 Clinical Trial at ASCO 2026 and Actively Seeks Partners for its Legacy Oncology Portfolio

Anaveon reports Clinical Benefit of ANV600 in the EXPAND-1 Phase 1 Clinical Trial at ASCO 2026 & actively seeks Partners for its Legacy Oncology Portfolio.
May 11, 2026 04:00 ET | Source: Anaveon

Anaveon Announces Presentation of Positive ANV600 Clinical Data at ASCO 2026 and Actively Seeks Partners for its Legacy Oncology Portfolio

Anaveon announces presentation of positive ANV600 Clinical Data at ASCO 2026 and actively seeks partners for its legacy Oncology Portfolio.
May 07, 2026 07:00 ET | Source: Entrada Therapeutics, Inc.

Entrada Therapeutics Announces Positive Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study

Entrada Therapeutics announces positive topline data from Cohort 1 of the Phase 1/2 ELEVATE-44-201 clinical study.
May 06, 2026 16:30 ET | Source: Entrada Therapeutics, Inc.

Entrada Therapeutics to Announce Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study on May 7, 2026

Entrada Therapeutics will announce topline results from Cohort 1 of the Phase 1/2 ELEVATE-44-201 clinical study of ENTR-601-44 on Thursday, May 7, 2026.
April 22, 2026 07:25 ET | Source: ALTERITY THERAPEUTICS LIMITED

Alterity Therapeutics Presents New Analysis of ATH434 Phase 2 Trial Data in Late Breaking Science Session of the American Academy of Neurology

- ATH434 reduced functional decline vs placebo at Week 52 on MuSyCA, a newly described MSA composite scale - - Effects seen on both daily function and neurological examination, consistent with...